Daniel Almquist is an Oncology physician. OpenAlex indexes 27 publications with 450 citations (h-index 9).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
820 4th St N
Fargo, ND 581024539
Telephone
701-234-3100Provider last certified this registry record 13 Jan 2023.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year20252 payments
- PFIZER INC.Program year20251 payment
- ABIOMEDProgram year202412 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
27%Opioid Agonist6.8%Oxycodone Hcl53%Hydromorphone Hcl28%Morphine Sulfate19%Part D<11 patientsPhenothiazine5.8%Prochlorperazine Maleate100%Part D≥52 patients+ 6 more classes in this area
Cancer & immunology
15.4%Aromatase Inhibitor5.7%Letrozole68%Anastrozole32%Part D<11 patientsKinase inhibitor3.6%Imbruvica65%Jakafi35%Part D<11 patients+ 3 more classes in this area
Metabolism & gastrointestinal
13.5%Corticosteroid4.1%Prednisone100%Part D≥16 patientsSerotonin-3 Receptor Antagonist3.3%Ondansetron Hcl100%Part D≥23 patients+ 4 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Optimizing mechanical thrombectomy – The impact of cath lab staff turnover on stroke thrombectomy times
Interventional Neuroradiology
2025 - Treatment landscape of advanced high-grade neuroendocrine neoplasms.
PubMed
2023 - Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: DIPNECH
Current Opinion in Pulmonary Medicine
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”